Sensyne Health plc
SSYNF
Other OTC0.00
USD
+0.00
- -
ISIN
GB00BYV3J755
Return %
Stock
S&P500
1Y
-95.79
26.57
3Y
-99.95
76.60
5Y
-99.95
78.48
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Alexander Charles Wallace Snow
- Full Time Employees
- 158
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- Schrodinger Building Oxford United Kingdom OX4 4GE
- IPO Date
- Aug 11, 2020
- Website
- sensynehealth.com
- Similar Companies
- Business
- Sensyne Health plc (ticker: SSYNF), a clinical artificial intelligence company founded in 2018 and headquartered in Oxford, United Kingdom, develops regulated medical software products and services that analyze ethically sourced, anonymized patient data in partnership with NHS Foundation Trusts and other healthcare systems to improve patient care, support clinical research, and accelerate drug discovery across therapeutic areas including cardiovascular, respiratory, diabetes, and heart failure; its core offerings include the SEND early warning system for monitoring vital signs such as pulse rate, temperature, blood pressure, oxygen saturation, and respiratory rate; GDm-Health, a digital diabetes management platform for pregnancy; EDGE, a chronic obstructive pulmonary disease management system; CleanSpace, an air pollution monitoring application; Support-HF, a heart failure patient management tool; and the SENSIGHT platform for real-world data interrogation, with operations spanning the UK and US. The company maintains strategic research agreements with multiple NHS trusts providing access to large-scale phenotypic datasets and has collaborated with pharmaceutical firms like Bayer on cardiovascular AI solutions and Phesi on clinical trial data integration reaching over 60 million patient records. In 2022, Sensyne Health underwent significant restructuring including termination of its formal sale process, delisting from the AIM market of the London Stock Exchange in June following shareholder approval and a revised financing agreement with noteholders, appointment of new CEO Alex Snow leading to rebranding elements as Arcturis with refocus on patient data for novel drug development, and securing £12.5 million in equity funding from investors such as Hambro Perks and Lansdowne Partners to support operations through 2025 amid divestitures of non-core units.